Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON | Zendy

Muh Geot Wong | Zendy; Vlado Perkovic | Zendy; John Chalmers | Zendy; Mark Woodward | Zendy; Qiang Li | Zendy; Mark E. Cooper | Zendy; Pavel Hamet | Zendy; Stephen Harrap | Zendy; Simon Heller | Zendy; Stephen MacMahon | Zendy; Giuseppe Mancia | Zendy; Michel Marre | Zendy; David R. Matthews | Zendy; Bruce Neal | Zendy; Neil R Poulter | Zendy; Anthony Rodgers | Zendy; Bryan Williams | Zendy; Sophia Zoungas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

Author(s) -

Muh Geot Wong,

Vlado Perkovic,

John Chalmers,

Mark Woodward,

Qiang Li,

Mark E. Cooper,

Pavel Hamet,

Stephen Harrap,

Simon Heller,

Stephen MacMahon,

Giuseppe Mancia,

Michel Marre,

David R. Matthews,

Bruce Neal,

Neil R Poulter,

Anthony Rodgers,

Bryan Williams,

Sophia Zoungas

Publication year - 2016

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc15-2322

Subject(s) - medicine , kidney disease , diabetes mellitus , dialysis , hazard ratio , intensive care medicine , type 2 diabetes , randomized controlled trial , cause of death , disease , endocrinology , confidence interval

The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research